An evolutionary conserved developmental program is carefully maintained in hematopoietic stem cells (HSCs). Genetic alterations and epigenetic mechanisms can alter the balance of normal blood development resulting in hematological malignancies. Our recent studies have identified MUSASHI (MSI2), as an RNA binding protein that controls normal and leukemia self-renewal. Moreover, the MSI family is highly expressed in the most aggressive solid tumors and we have demonstrated that MSI2 expression predicts a worse clinical prognosis in acute myeloid leukemia (AML). We hypothesize that the RNA binding proteins MSI2 controls leukemic stem cell self-renewal and elucidating the mechanism of action for MSI2 in LSCs may provide novel therapeutic strategies in myeloid leukemia. This proposal utilizes Msi2 conditional knockouts and patient samples with AML to dissect the requirement for MSI2 in leukemia self-renewal. Furthermore, our global genetic approaches have already uncovered how regulation of translation alters several epigenetic pathways that are controlled by the MLL-AF9 oncogene. Our studies will examine the direct mRNA targets of MSI2 that control LSC function. Additionally, we will stratify patients based on their MSI2 expression and determine how cytotoxic agents, molecular targeted and epigenetic therapies can be used to improve therapeutic outcomes in AML.

Public Health Relevance

Although molecular targeted therapy has dramatically changed how we treat cancer, the treatment for acute myeloid leukemia (AML) remains focused on the use of cytotoxic drugs with many patients eventually relapsing with their disease. Our recent studies have uncovered a stem cell related factor called MUSASHI2 that is overexpressed in many AMLs. This proposal studies this factor in both mouse models and in human AML in order to identify novel strategies for targeting the stem cell program in leukemia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA193842-02
Application #
9033110
Study Section
Molecular Oncogenesis Study Section (MONC)
Program Officer
Mufson, R Allan
Project Start
2015-04-01
Project End
2020-03-31
Budget Start
2016-04-01
Budget End
2017-03-31
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Jee, David; Yang, Jr-Shiuan; Park, Sun-Mi et al. (2018) Dual Strategies for Argonaute2-Mediated Biogenesis of Erythroid miRNAs Underlie Conserved Requirements for Slicing in Mammals. Mol Cell 69:265-278.e6
Kharas, Michael G; Lengner, Christopher J (2017) Stem Cells, Cancer, and MUSASHI in Blood and Guts. Trends Cancer 3:347-356
Wang, K; Sanchez-Martin, M; Wang, X et al. (2017) Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias. Leukemia 31:151-158
Kotini, Andriana G; Chang, Chan-Jung; Chow, Arthur et al. (2017) Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. Cell Stem Cell 20:315-328.e7
Bhagat, Tushar D; Chen, Si; Bartenstein, Matthias et al. (2017) Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/?-Catenin Activation. Cancer Res 77:4846-4857
Vu, Ly P; Prieto, Camila; Amin, Elianna M et al. (2017) Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nat Genet 49:866-875
Yousefi, Maryam; Li, Ning; Nakauka-Ddamba, Angela et al. (2016) Msi RNA-binding proteins control reserve intestinal stem cell quiescence. J Cell Biol 215:401-413
Taggart, James; Ho, Tzu-Chieh; Amin, Elianna et al. (2016) MSI2 is required for maintaining activated myelodysplastic syndrome stem cells. Nat Commun 7:10739
Park, Sun-Mi; Gönen, Mithat; Vu, Ly et al. (2015) Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. J Clin Invest 125:1286-98